Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

20131,485 citationsJournal Article

Authors

John W. Eikelboom · McMaster University

Stuart J. Connolly · Hamilton Health Sciences

Martina Brueckmann · University of Mannheim

Christopher B. Granger · Erasmus MC

A. Pieter Kappetein · Erasmus MC

Michael J. Mack · Heart Hospital Baylor Plano

Jon Blatchford ·

Abstract

The use of dabigatran in patients with mechanical heart valves was associated with increased rates of thromboembolic and bleeding complications, as compared with warfarin, thus showing no benefit and an excess risk. (Funded by Boehringer Ingelheim; ClinicalTrials.gov numbers, NCT01452347 and NCT01505881.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Cardiac Valve Diseases and Treatments Cardiac Arrhythmias and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 13, pp. 1206-1214

DOI: 10.1056/nejmoa1300615

Field-Weighted Citation Impact: 86.75